

# Gregory J Keir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2384816/publications.pdf>

Version: 2024-02-01

21  
papers

1,315  
citations

687363

13  
h-index

794594

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1429  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab in severe, treatmentâ€refractory interstitial lung disease. <i>Respirology</i> , 2014, 19, 353-359.	2.3	217
2	An integrated clinicroadiological staging system for pulmonary sarcoidosis: a case-cohort study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 123-130.	10.7	178
3	Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. <i>Thorax</i> , 2014, 69, 216-222.	5.6	176
4	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. <i>European Respiratory Journal</i> , 2017, 49, 1601592.	6.7	174
5	Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. <i>European Respiratory Journal</i> , 2012, 40, 641-648.	6.7	123
6	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 275.	1.6	121
7	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. <i>BMC Pulmonary Medicine</i> , 2018, 18, 19.	2.0	58
8	Assessing Pulmonary Disease and Response to Therapy: Which Test?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 409-418.	2.1	51
9	Diagnosis and management of connective tissue diseaseâ€associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. <i>Respirology</i> , 2021, 26, 23-51.	2.3	45
10	Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia. <i>Respirology</i> , 2017, 22, 1436-1458.	2.3	39
11	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. <i>Respirology</i> , 2018, 23, 687-694.	2.3	39
12	Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. <i>Thorax</i> , 2014, 69, 287-288.	5.6	28
13	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. <i>ERJ Open Research</i> , 2018, 4, 00124-2017.	2.6	16
14	Direct oral anticoagulants for cancerâ€associated venous thromboembolisms: a systematic review and network metaâ€analysis. <i>Internal Medicine Journal</i> , 2022, 52, 272-281.	0.8	14
15	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. <i>Medical Journal of Australia</i> , 2018, 208, 82-88.	1.7	13
16	Peer Connect Service for people with pulmonary fibrosis in Australia: Participants' experiences and process evaluation. <i>Respirology</i> , 2020, 25, 1053-1059.	2.3	13
17	Eligibility for antiâ€fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. <i>Respirology</i> , 2019, 24, 988-995.	2.3	7
18	Pulmonary Vasospasm in Systemic Sclerosis: Noninvasive Techniques for Detection. <i>Pulmonary Circulation</i> , 2015, 5, 498-505.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Use of direct oral anticoagulants for acute pulmonary embolisms in obesity: a propensity-matched, multicentre caseâ€“control study. ERJ Open Research, 2021, 7, 00379-2021.	2.6	1
20	Thrombolysis for massive pulmonary embolisms in morbid obesity: a multisite caseâ€“control study. ERJ Open Research, 2021, 7, 00762-2020.	2.6	0
21	Unravelling the enigma of <scp>systemic lupus erythematosus</scp>â€™associated <scp>ILD</scp>. Respirology, 2022, 27, 567-568.	2.3	0